【摘要】 目的观察人乳癌新辅助化疗前后MCM5、Ki-67和C-erbB-2蛋白的表达情况,探讨其与化疗效果的关系。方法采用免疫组化法检测新辅助化疗前后40例乳癌标本中MCM5、Ki-67和C-erbB-2的表达。结果新辅助化疗有效率为77.5%。化疗前MCM5和Ki-67蛋白阳性表达显著高于化疗后(Z=-3.94、-3.04,P<0.01),而化疗前后C-erbB-2蛋白阳性表达差异无显著性(Z=-1.60,P>0.05);化疗前MCM5蛋白阳性表达显著高于Ki-67(Z=-4.02,P<0.01)。化疗有效组(31例)MCM5蛋白阳性表达显著高于化疗无效组(9例)(Z=-3.57,P<0.01),而C-erbB-2蛋白阳性表达显著低于化疗无效组(Z=-3.92,P<0.01)。结论ET方案新辅助化疗有较好的疗效,可能通过抑制MCM5、Ki-67蛋白的表达来阻止乳癌细胞的增殖。MCM5高表达、C-erbB-2阴性者化疗更为敏感,二者可作为临床指导乳癌化疗的分子生物学指标。更多还原

【Abstract】 Objective To study the expressions of MCM5,Ki-67,and C-erbB-2 before and after neoadjuvant chemotherapy(NC) in breast cancer patients,analyze their relationship with response to NC. Methods The expressions of MCM5,Ki-67,and C-erbB-2 before and after NC were examined by immunohistochemistry in 40 patients with breast cancer. Results The overall response rate to NC was 77.5%.The positive expression of MCM5 and Ki-67 before the therapy was significantly higher than that after(Z=-3.94,-3.04;P<0.01),while there was no significant difference in the expression of C-erbB-2 between before and after chemotherapy(Z=-1.60,P>0.05).Before the chemotherapy,the positive expression of MCM5 was significantly higher than that of Ki-67(Z=-4.02,P<0.01).The positive MCM5 in the chemotherapy-effective group(31 cases) was higher than that of the chemotherapy-uneffective(9 cases)(Z=-3.57,P<0.01),and the positive expression of C-erbB-2 was significantly lower(Z=-3.92,P<0.01). Conclusion Neoadjuvant chemotherapy with ET regimen is effective for breast cancer,which inhibits the proliferatation of cancer cells by restraining the expression of MCM5 and Ki-67.Patients with high expression of MCM5 and negative C-erbB-2 are more likely to respond to the therapy.Both MCM5 and C-erbB-2 can be used as molecular biological markers to guide chemotherapy for breast cancer.更多还原